FindTrial
Sign In

Phase II trial of transdermic buprenorfine in children with pain cancer - ND

Phase II trial of transdermic buprenorfine in children with pain cancer - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-007042-35-IT
Enrollment
Unknown
Registered
2007-12-17
Start date
2008-04-04
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain cancer in children MedDRA version: 6.1 Level: PT Classification code 10027484

Interventions

Trade Name: TRANSTEC Pharmaceutical Form: Transdermal patch INN or Proposed INN: Buprenorphine Concentration unit: µg/kg microgram(s)/kilogram Concentration type: equal Concentration number: 35-

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: children (age:>3 and> 18) with pain cancer Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: age 18 opiates ipersensitivity

Design outcomes

Primary

MeasureTime frame
Main Objective: effectivness and tollerability of transdermic buprenorfine;Secondary Objective: nd;Primary end point(s): nd—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026